Stock FLAC FRAZIER LIFESCIENCES ACQUISITION CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Frazier Lifesciences Acquisition Corporation

Equities

FLAC

KYG3710A1058

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration

Latest news about Frazier Lifesciences Acquisition Corporation

Frazier Lifesciences Acquisition Corporation Announces Executive Changes CI
Frazier Lifesciences Acquisition Corporation(NasdaqCM:FLAC) dropped from NASDAQ Composite Index CI
NewAmsterdam Pharma B.V. completed the acquisition of Frazier Lifesciences Acquisition Corporation from a group of shareholders in a reverse merger transaction. CI
Frazier Lifesciences Shareholders Approve Merger With NewAmsterdam Pharma Holding MT
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
NewAmsterdam Pharma to Go Public in Deal With Frazier Lifesciences SPAC MT
NewAmsterdam Pharma B.V. entered into a definitive business combination agreement to acquire Frazier Lifesciences Acquisition Corporation from a group of shareholders for approximately $490 million. CI
Frazier Lifesciences Acquisition Negotiates Business Combination With NewAmsterdam Pharma MT
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Frazier Lifesciences Acquisition Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Frazier Lifesciences Acquisition Corporation Auditor Raises 'Going Concern' Doubt CI
Certain Class B Ordinary Shares of Frazier Lifesciences Acquisition Corporation are subject to a Lock-Up Agreement Ending on 6-JUN-2021. CI
Frazier Lifesciences Acquisition Corp.(NasdaqCM:FLAC) added to NASDAQ Composite Index CI
Frazier Lifesciences Acquisition Corp. announced that it has received $5.01 million in funding from Frazier Lifesciences Sponsor LLC CI
Frazier Lifesciences Acquisition Corporation has completed an IPO in the amount of $120 million. CI
Frazier Lifesciences Acquisition Corporation has filed an IPO in the amount of $100 million. CI
Frazier Lifesciences Acquisition Corp. announced that it expects to receive $4.25 million in funding from Frazier Lifesciences Sponsor LLC CI

Chart Frazier Lifesciences Acquisition Corporation

Chart Frazier Lifesciences Acquisition Corporation
More charts

Company Profile

Frazier Lifesciences Acquisition Corporation is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. It intends to identify opportunities in the biotechnology sector. It has conducted no operations and has generated no revenues.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. FLAC Stock
  4. News Frazier Lifesciences Acquisition Corporation
  5. NewAmsterdam Pharma to Go Public in Deal With Frazier Lifesciences SPAC